<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">NIEDER, CARSTEN</style></author><author><style face="normal" font="default" size="100%">DALHAUG, ASTRID</style></author><author><style face="normal" font="default" size="100%">PAWINSKI, ADAM R.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">675-678</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.11822</style></doi><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Previous research has suggested that patients with metastatic renal cell cancer (mRCC) and bone metastases have a poorer prognosis compared to their counterparts with no skeletal involvement. Therefore, we analyzed the management and outcomes of such patients in our center. Patients and Methods: We performed a retrospective study of 35 consecutive patients who received systemic treatment, largely targeted therapy, for mRCC with bone metastases. Results: The median overall survival was 25 months from the time of diagnosis of mRCC. The 5-year survival rate was 16%. Survival from diagnosis of mRCC was significantly worse in patients with bone metastases present at the start of first-line systemic therapy (median 13 months) compared to delayed metastases diagnosed later during the course of disease (46 months, p=0.01). Few patients (29%) were able to receive more than two lines of systemic therapy. Bone-only metastases were uncommon (11%). Conclusion: Most patients with mRCC and bone metastases have limited overall survival.</style></abstract></record></records></xml>